In HR+ NSCLC, there was no significant difference in the prevalence of EGFR mutations (69/318, 21.70% vs. 33/186, 17.74%,; p = 0.3032, q=0.3826) in females. This evidence concerns the gene EGFR and non-small cell lung carcinoma.